EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In utero and postnatal ivacaftor/lumacaftor therapy rescues multiorgan disease in CFTR-F508del ferrets

Idil Apak Evans, Xingshen Sun, Bo Liang, Amber R Vegter, Lydia Guo, Thomas J Lynch, Yan Zhang, Yulong Zhang, Yaling Yi, Yu Yang, Zehua Feng, Soo Yeun Park und 14 weitere

JCI Insight · 2024

DOI: 10.1172/jci.insight.157229 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCI Insight, 2024. Verfasst von Idil Apak Evans und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy and Cell Biology, and. Hauptthemen laut MEDLINE: Aminophenols, Aminopyridines, Benzodioxoles, Cystic Fibrosis. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIEHS NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator ( CFTR ) gene, with F508del being the most prevalent mutation. The combination of CFTR modulators (potentiator and correctors) has provided benefit to CF patients carrying the F508del mutation; however, the safety and effectiveness of in utero combination modulator therapy remains unclear. We created a F508del ferret model to test whether ivacaftor/lumacaftor (VX-770/VX-809) therapy can rescue in utero and postnatal pathologies associated with CF. Using primary intestinal organoids and air-liquid interface cultures of airway epithelia, we demonstrate that the F508del mutation in ferret CFTR results in a severe folding and trafficking defect, which can be partially restored by treatment with CFTR modulators. In utero treatment of pregnant jills with ivacaftor/lumacaftor prevented meconium ileus at birth in F508del kits and sustained postnatal treatment of CF offspring improved survival and partially protected from pancreatic insufficiency. Withdrawal of ivacaftor/lumacaftor treatment from juvenile CF ferrets reestablished pancreatic and lung diseases, with altered pulmonary mechanics. These findings suggest that in utero intervention with a combination of CFTR modulators may provide therapeutic benefits to individuals with F508del. This CFTR -F508del ferret model may be useful for testing therapies using clinically translatable endpoints.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminophenolsAminopyridinesBenzodioxolesCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorFerretsQuinolonesAnimalsFemalePregnancyChloride Channel AgonistsDisease Models, AnimalDrug CombinationsMutation

Stichwörter der Autor:innen

Bacterial infectionsGenetic diseasesPulmonologyTherapeutics

Substanzen

AminophenolsAminopyridinesBenzodioxolesChloride Channel AgonistsCystic Fibrosis Transmembrane Conductance RegulatorDrug Combinationsivacaftorlumacaftor, ivacaftor drug combinationQuinoloneslumacaftor

Autor:innen und Institutionen

  • Department of Anatomy and Cell Biology, and.
  • Department of Biostatistics, University of Iowa College of Public Health, Iowa City, Iowa, USA.
  • Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA.
  • Department of Microbiology and Immunology, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA.
  • Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA.

Förderung

  • NIGMS NIH HHS
  • NIEHS NIH HHS
  • NHLBI NIH HHS
  • NIDDK NIH HHS
  • National Institutes of Health
  • Cystic Fibrosis Foundation

Zitieren

APA

Evans, I. A., Sun, X., Liang, B., Vegter, A. R., Guo, L., Lynch, T. J., Zhang, Y., Zhang, Y., Yi, Y., Yang, Y., Feng, Z., Park, S. Y., Shonka, A., McCumber, H., Qi, L., Wu, P., Liu, G., Lacina, A., Wang, K., …, & Engelhardt, J. F. (2024). In utero and postnatal ivacaftor/lumacaftor therapy rescues multiorgan disease in CFTR-F508del ferrets. JCI Insight. https://doi.org/10.1172/jci.insight.157229

Vancouver

Evans IA, Sun X, Liang B, Vegter AR, Guo L, Lynch TJ, et al. In utero and postnatal ivacaftor/lumacaftor therapy rescues multiorgan disease in CFTR-F508del ferrets. JCI Insight. 2024. doi:10.1172/jci.insight.157229

BibTeX
@article{Evans2024,
  author = {Evans, Idil Apak and Sun, Xingshen and Liang, Bo and Vegter, Amber R and Guo, Lydia and Lynch, Thomas J and Zhang, Yan and Zhang, Yulong and Yi, Yaling and Yang, Yu and Feng, Zehua and Park, Soo Yeun and Shonka, Amanita and McCumber, Hannah and Qi, Lisi and Wu, Peipei and Liu, Guangming and Lacina, Allison and Wang, Kai and Gibson-Corley, Katherine N and Meyerholz, David K and Limoli, Dominique H and Rosen, Bradley H and Yan, Ziying and Bartels, Douglas J and Engelhardt, John F},
  title = {In utero and postnatal ivacaftor/lumacaftor therapy rescues multiorgan disease in CFTR-F508del ferrets},
  journal = {JCI Insight},
  year = {2024},
  doi = {10.1172/jci.insight.157229}
}
Kostenlos starten →